Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function

التفاصيل البيبلوغرافية
العنوان: Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function
المؤلفون: Maud Jost, Virginie Kinet, Ingrid Duijkers, Jean-Michel Foidart, Christine Klipping, Adriana Bastidas
المصدر: Contraception. 103(6)
سنة النشر: 2020
مصطلحات موضوعية: medicine.medical_specialty, medicine.drug_class, media_common.quotation_subject, Ovulation Inhibition, Ethinyl Estradiol, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Ethinylestradiol, Follicular phase, medicine, Humans, 030212 general & internal medicine, Ovulation, media_common, 030219 obstetrics & reproductive medicine, Estradiol, business.industry, Estetrol, Obstetrics and Gynecology, Drospirenone, Estrogens, Contraceptives, Oral, Combined, Endocrinology, Reproductive Medicine, chemistry, Estrogen, Androstenes, Female, Luteinizing hormone, business, medicine.drug
الوصف: Objective To evaluate the effects of estetrol 15 mg/drospirenone 3 mg on ovarian function. Study design Single-center, randomized, open-label, parallel study in healthy young women with proven ovulatory cycles. Participants received either estetrol 15 mg/drospirenone 3 mg (E4/DRSP) (n = 41) or ethinylestradiol 20 µg/drospirenone 3 mg (EE/DRSP) (n = 41) in a 24/4-day regimen for 3 consecutive cycles. Follicular size and endometrial thickness were measured by transvaginal ultrasound every 3 days in cycles 1 and 3. Blood was sampled for hormone analysis. Ovarian function expressed as Hoogland score was based on follicular size, serum estradiol (E2) and progesterone (P) concentrations. Ovulation was defined as a ruptured follicle-like structure >13 mm with serum E2 concentrations >100 pmol/L and serum P concentrations >5 nmol/L. We assessed return of ovulation after treatment cessation, and safety throughout the study. Results None of the participants ovulated with E4/DRSP use, while one participant ovulated once and one participant ovulated twice during EE/DRSP treatment. Most participants had a Hoogland score of 1 (no ovarian activity) in cycle 1 (85.0% and 82.9% of participants on E4/DRSP and EE/DRSP, respectively) and in cycle 3 (65.8% and 83.8%, respectively). E4/DRSP suppressed follicle-stimulating hormone and luteinizing hormone to a lesser extent than EE/DRSP, whereas both treatments comparably suppressed E2 and P and endometrial thickness. Return of ovulation occurred, on average, 15.5 days after E4/DRSP treatment discontinuation. E4/DRSP was safe and well-tolerated. Conclusions E4 15 mg/DRSP 3 mg results in adequate ovulation inhibition and ovarian function suppression, comparable to a marketed combined oral contraceptive containing EE/DRSP. Implications statement Treatment with E4 15 mg/DRSP 3 mg showed complete ovulation inhibition, despite less suppression of follicle-stimulating hormone and luteinizing hormone compared to EE/DRSP. If it becomes commercially available, E4/DRSP, containing a naturally occurring estrogen, should be as effective as EE/DRSP.
تدمد: 1879-0518
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d42fdbd9db9babbd64aced852dafd71Test
https://pubmed.ncbi.nlm.nih.gov/33689786Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....1d42fdbd9db9babbd64aced852dafd71
قاعدة البيانات: OpenAIRE